APPLIED DNA SCIENCES INC
Form 8-K/A
May 07, 2018
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K/A
Amendment No.1
CURRENT REPORT
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): March 31, 2018

Applied DNA Sciences, Inc.

(Exact name of registrant as specified in its charter)

Delaware	001-36745	59-2262718
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)
50 Health Sciences Drive		
Stony Brook, New York	11790	
(Address of principal execution)	utive offices; zip code)	
Registrant's telephone nun	nber, including area code:	
N/A		
(Former name or former ac	ldress, if changed since last	report)
Check the appropriate box the registrant under any of		g is intended to simultaneously satisfy the filing obligation of
"Written communications	pursuant to Rule 425 under	the Securities Act (17 CFR 230.425)
"Soliciting material pursu	ant to Rule 14a-12 under the	e Exchange Act (17 CFR 240.14a-12)
"Pre-commencement com	munications pursuant to Ru	le 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
"Pre-commencement com	munications pursuant to Rui	le 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the

of this chapter). Emerging growth company "

Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. "

Explanatory Note:

This Form 8-K/A amends the Current Report on Form 8-K, which was originally filed on April 5, 2018 (the "Original 8-K"), solely to correct a typographical error in the descriptive title of Item 7.01 which should read "Regulation FD Disclosure". The text of Item 7.01 is not changed.

Item 7.01. Regulation FD Disclosure

On March 31, 2018, Applied DNA Sciences, Inc. (the "Company") entered into a License and Cooperation Agreement and a related Supply Agreement (the "Agreements") effective March 31, 2018, with Colorcon, Inc. ("Colorcon") for the use of the Company's SigNatur® molecular tags in Colorcon's pharmaceutical and neutraceutical product offerings and access to the Company's associated authentication technologies. The Company issued a press release announcing the Agreements on April 5, 2018. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d)Exhibits

- 99.1 Press Release issued by Applied DNA Sciences, Inc. dated April 5, 2018 announcing agreements with Colorcon, Inc. (1)
- (1) Previously filed as an exhibit to the Original 8-K.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 7, 2018 APPLIED DNA SCIENCES, INC.

By: /s/ James A. Hayward Name: James A. Hayward Title: Chief Executive Officer

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press Release issued by Applied DNA Sciences, Inc. dated April 5, 2018 announcing agreements with Colorcon, Inc. (1)

(1) Previously filed as an exhibit to the Original 8-K.